Adam Duvall, MD, MPH, spotlights new research further elucidating the role of blinatumomab in the acute lymphoblastic leukemia treatment paradigm.
Treatment Trends in Adult and Pediatric Acute Lymphoblastic Leukemia
Adam DuVall, MD, MPH, discusses remaining questions regarding the optimal use of blinatumomab in frontline B-ALL.
Ryan Cassaday, MD, discussed insights from trials investigating blinatumomab in patients with B-ALL that were reported at the 2024 ASH Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5